跳至主要内容
临床试验/ISRCTN74802813
ISRCTN74802813已完成未知

A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma

Medical Research Council (UK)0 个研究点目标入组 550 人开始时间: 2006年1月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
550

研究概览

简要总结

2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26002111 results

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Clinical and imaging evidence of a pelvic mass with extrapelvic metastatic disease at presentation
  • 2. Randomisation should be carried out within 4 weeks of obtaining clinical and imaging evidence of disease
  • 3. Serum Cancer Antigen (CA 125) / CarcinoEmbryonic Antigen (CEA) ratio >25 (if the serum CA 125/CEA is less than or equal to 25 and the serum CEA is above the upper limit of normal, the patient should undergo investigations to exclude gastrointestinal cancer)
  • 4. Patient planned to receive carboplatin-based chemotherapy
  • 5. Patient fit to undergo protocol treatment and follow-up
  • 6. No concomitant or previous malignancy likely to interfere with protocol treatments or comparisons
  • 7. Written informed consent of the patient

排除标准

  • 未提供

研究者

发起方
Medical Research Council (UK)

相似试验